Low CAVIN3 expression was associated with better radiotherapy response in cervical cancer
Low CAVIN3 expression was associated with higher treatment response and substantially longer progression-free survival after radiotherapy for cervical cancer.
Low CAVIN3 expression was associated with higher treatment response and substantially longer progression-free survival after radiotherapy for cervical cancer.
Task-specific deep learning halved pelvic artifact burden, improved applicator reconstruction to 0.1 mm, and shortened organ contouring by up to 40%.
Nine-field intensity-modulated radiotherapy shortened overall planning-plus-delivery time and improved several pelvic dose metrics compared with volumetric modulated arc therapy.
Daily online adaptation improved pelvic target coverage during 17-fraction cervical chemoradiotherapy, with 10% grade ≥3 gastrointestinal toxicity.
Retroverted uterine position increased rectal and bowel dose during cervical brachytherapy, but survival, recurrence and severe toxicity remained comparable.
Template-guided implantation achieved a median HR-CTV D90 of 92.9 Gy with low severe toxicity across 555 brachytherapy fractions.
PocketNet matched nnU-Net accuracy for cervical MRI segmentation while using 40-fold less storage and approximately half the training time.
A 55-gene hypoxia classifier independently predicted worse survival and retained prognostic value across Manchester, Seoul, and Norwegian cervical cancer cohorts.
Iodine-125 seed implantation produced 90% three-month disease control, but median local progression-free survival was nine months.
Pretreatment lymphocyte-to-monocyte ratio was independently associated with cervical tumour shrinkage, but its standalone discrimination was poor.
EQD2 should remain the reporting standard, but delivery time, dose gradients, biological assumptions and dose accumulation materially affect its interpretation.
All patients receiving more than 8 Gy mean dose or 16 Gy maximum dose to the least exposed ovary developed premature ovarian insufficiency.
A score above seven identified patients with treatment beyond 56 days in 53.6% versus 17.8% at lower scores.
Adding radiotherapy to systemic treatment was associated with longer overall and progression-free survival without significantly higher acute toxicity.
A nodal-to-primary tumor volume ratio of at least 15% was associated with lower three-year distant metastasis-free survival after extended-field radiotherapy.